278 related articles for article (PubMed ID: 28396848)
1. Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine.
Soldera SV; Leighl NB
Front Oncol; 2017; 7():50. PubMed ID: 28396848
[TBL] [Abstract][Full Text] [Related]
2. Mutational Landscape of DDR2 Gene in Lung Squamous Cell Carcinoma Using Next-generation Sequencing.
Ricordel C; Lespagnol A; Llamas-Gutierrez F; de Tayrac M; Kerjouan M; Fievet A; Hamdi-Rozé H; Aliouat A; Desrues B; Mosser J; Léna H
Clin Lung Cancer; 2018 Mar; 19(2):163-169.e4. PubMed ID: 29129434
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients.
Miao L; Wang Y; Zhu S; Shi M; Li Y; Ding J; Yang J; Ye Q; Cai H; Zhang D; Liu H; Song Y
BMC Cancer; 2014 May; 14():369. PubMed ID: 24885564
[TBL] [Abstract][Full Text] [Related]
4. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.
Perez-Moreno P; Brambilla E; Thomas R; Soria JC
Clin Cancer Res; 2012 May; 18(9):2443-51. PubMed ID: 22407829
[TBL] [Abstract][Full Text] [Related]
5. Personalized therapy on the horizon for squamous cell carcinoma of the lung.
Kim HS; Mitsudomi T; Soo RA; Cho BC
Lung Cancer; 2013 Jun; 80(3):249-55. PubMed ID: 23489560
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.
Lee MS; Jung EA; An SB; Kim YJ; Oh DY; Song JY; Um SW; Han J; Choi YL
Cancer Res Treat; 2017 Oct; 49(4):1065-1076. PubMed ID: 28161936
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Chung C
J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
[TBL] [Abstract][Full Text] [Related]
8. Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC.
Zer A; Leighl N
Front Oncol; 2014; 4():329. PubMed ID: 25505733
[TBL] [Abstract][Full Text] [Related]
9. Genetic insight and therapeutic targets in squamous-cell lung cancer.
Sos ML; Thomas RK
Oncogene; 2012 Nov; 31(46):4811-4. PubMed ID: 22266863
[TBL] [Abstract][Full Text] [Related]
10. The continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung.
Tan WL; Ng QS
Transl Lung Cancer Res; 2016 Feb; 5(1):106-9. PubMed ID: 26958503
[TBL] [Abstract][Full Text] [Related]
11. Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study.
Chang Q; Qiang H; Qian J; Lei Y; Lu J; Feng H; Zhao Y; Han B; Zhang Y; Chu T
Front Oncol; 2021; 11():652560. PubMed ID: 33869057
[TBL] [Abstract][Full Text] [Related]
12. Incomplete epithelial-mesenchymal transition in p16-positive squamous cell carcinoma cells correlates with β-catenin expression.
Umbreit C; Flanjak J; Weiss C; Erben P; Aderhold C; Faber A; Stern-Straeter J; Hoermann K; Schultz JD
Anticancer Res; 2014 Dec; 34(12):7061-9. PubMed ID: 25503133
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis.
Ameratunga M; Pavlakis N; Gebski V; Broad A; Khasraw M
Asia Pac J Clin Oncol; 2014 Sep; 10(3):273-8. PubMed ID: 25135201
[TBL] [Abstract][Full Text] [Related]
15. Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.
Tagliamento M; Genova C; Rijavec E; Rossi G; Biello F; Dal Bello MG; Alama A; Coco S; Boccardo S; Grossi F
Expert Opin Pharmacother; 2018 Dec; 19(18):2055-2062. PubMed ID: 30392436
[TBL] [Abstract][Full Text] [Related]
16. Squamous cell lung cancer: from tumor genomics to cancer therapeutics.
Gandara DR; Hammerman PS; Sos ML; Lara PN; Hirsch FR
Clin Cancer Res; 2015 May; 21(10):2236-43. PubMed ID: 25979930
[TBL] [Abstract][Full Text] [Related]
17. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?
Tsironis G; Ziogas DC; Kyriazoglou A; Lykka M; Koutsoukos K; Bamias A; Dimopoulos MA
Ann Transl Med; 2018 Apr; 6(8):143. PubMed ID: 29862232
[TBL] [Abstract][Full Text] [Related]
18. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
19. Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.
Hall PE; Spicer J; Popat S
Future Oncol; 2015; 11(15):2175-91. PubMed ID: 26039665
[TBL] [Abstract][Full Text] [Related]
20. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
